Ipx-822 [portable] May 2026

The landscape of hepatology is currently witnessing a significant shift toward targeted molecular therapies, with (often referred to in development contexts similar to the IPX or INI prefixes) emerging as a prominent candidate for treating chronic liver conditions. Developed by Inipharm , this investigational drug is designed to address the unmet medical need in metabolic-associated steatotic liver disease (MASLD), formerly known as NASH (non-alcoholic steatohepatitis). Mechanism and Scientific Foundation